secretory carcinoma

se·cre·to·ry car·ci·no·ma

carcinoma of the breast with pale-staining cells showing prominent secretory activity, as seen in pregnancy and lactation, but found mostly in children.
Synonym(s): juvenile carcinoma

se·cre·to·ry car·ci·no·ma

(sē'krĕ-tōr-ē kahr'si-nō'mă)
Cancer of the breast with pale-staining cells showing prominent secretory activity, as seen in pregnancy and lactation, but found mostly in children.
Mentioned in ?
References in periodicals archive ?
Takahashi et al., "Cytological features of mammary analogue secretory carcinoma of salivary gland: fine-needle aspiration of seven cases," Diagnostic Cytopathology, vol.
Definition: Mammary analogue secretory carcinoma (MASC) is a low-grade malignant tumor of salivary glands resembling secretory breast carcinoma, including histopathologic and immunohistochemical features and t(12;15)(p13;q25) translocation with ETV6-NTRK3 gene fusion.
Chrissy had breast cancer - a rare form called secretory carcinoma, which affects one in a million women in the US.
These include commons SGTs such as mucoepidermoid carcinomas (MEC), adenoid cystic carcinoma (AdCC), and the newly described entity mammary analog secretory carcinoma (MASC).
of Type of Tumour Cases Percentage Invasive ductal 41 80.39 carcinoma Medullary carcinoma 4 7.84 Colloid carcinoma 1 1.96 Infiltrative lobular 1 1.96 carcinoma Secretory carcinoma 1 1.96 Invasive papillary 1 1.96 Comedocarcinoma 1 1.96 Ductal carcinoma 1 1.96 in-situ Paget's disease 0 0 Cystosarcoma 0 0 phylloid Others 0 0 Total 51 99.99 Table 6: Histopathoiogical Nodal Involvement No.
There is very rare expression of NTRK fusion but in various adult and pediatric solid tumors, including infantile fibrosarcoma, glioma, glioblastoma, diffuse intrinsic pontine glioma (DIPG), congenital mesoblastic nephroma, melanoma, inflammatory myofibroblastic tumor (IMT), uterus sarcoma, soft tissue tumor, gastrointestinal stromal tumor (GIST), secretory carcinoma of breast, secretory carcinoma of salivary gland, cancer of unknown primary, lung cancer, colorectal cancer, appendiceal cancer, breast cancer, gastric cancer, ovarian cancer, thyroid cancer, cholangiocarcinoma, pancreatic cancer, head and neck cancer, and various sarcomas.
Mammary analog secretory carcinoma (MASC) was first described in 2010 as a rare salivary gland malignancy characterized by its similarities to breast secretory carcinoma by histology, immunohistochemistry, and genetics.
The trial demonstrated that entrectinib was well tolerated and positive responses were observed in non-small cell lung cancer (NSCLC), colorectal cancer, mammary analog secretory carcinoma (MASC), melanoma and renal cell carcinoma.
[35] Of the 268 malignant lesions, most common diagnosis was infiltrating duct carcinoma (N = 229), followed by medullary carcinoma (N = 2) and mucinous carcinoma, infiltrating lobular carcinoma, sarcomatoid carcinoma, invasive papillary carcinoma, and secretory carcinoma with one case each [Table 3].
Chrissy Turner noticed a lump on her chest and tests confirmed she had secretory carcinoma.
The noteworthy or emerging markers mentioned in this review include S100, mammaglobin, vimentin, EMA, and balanced translocation t(12;15)(p13;q25) for mammary-analog secretory carcinoma; microphthalmia-associated transcription factor (MITF) and SOX10 for mucosal melanoma; diffusely positive p40 and p63 for basaloid squamous cell carcinoma; p63, Epstein-Barr virus-encoded small RNA (EBER), and latent membrane protein 1 (LMP-1) for nasopharyngeal carcinoma; loss of parafibromin, galectin3 overexpression, increased Ki-67 index, and expression of protein gene product 9.5 (PGP9.5) for parathyroid carcinoma (versus adenoma); and EMA, CK, and CD117 labeling epithelial cells and p63, smooth muscle actin (SMA), and S100 labeling myoepithelial cells for epithelial-myoepithelial carcinoma.